Associated tags: FDA, Blepharoplasty, Pharmaceutical industry, Patient, Aneurysm, Headache, Horner's syndrome, Hypertension, Xanthine oxidase inhibitor, Eye injury, Myasthenia gravis, Eye, Stroke, Blood pressure, Glaucoma, Ptosis
Locations: BRIDGEWATER, NJ, US, UNITED STATES, NEW YORK CITY, DELAWARE, NEW YORK
Retrieved on:
Monday, November 27, 2023
BRIDGEWATER, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc. (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelids, in adults, today announced that it and its wholly-owned U.S. operating subsidiary RVL Pharmacy, LLC (collectively, the “RVL Subsidiaries”), successfully emerged from their Chapter 11 cases on November 22, 2023 following the confirmation by the United States Bankruptcy Court for the District of Delaware of their Plan of Reorganization (“Plan”) on November 20, 2023. RevitaLid Pharmaceutical Corp., previously the direct parent company of RVL Pharmaceuticals, Inc, concurrently emerged from its Chapter 11 case, though will be wound down under the Plan.
Key Points:
- RevitaLid Pharmaceutical Corp., previously the direct parent company of RVL Pharmaceuticals, Inc, concurrently emerged from its Chapter 11 case, though will be wound down under the Plan.
- “Upon emergence, the RVL Subsidiaries are well-positioned to invest in UPNEEQ, drive their strategic initiatives, and continue to deliver high-quality, innovative ocular and aesthetic solutions for patients and healthcare partners,” said Brian Markison, Chief Executive Officer of the Company.
- The Plan was unanimously supported by the RVL Subsidiaries’ sole secured lender (funds managed by Athyrium Capital Management, LP (“Athyrium”)) and other key stakeholders.
- It is expected the wind-down of the Company’s former public parent company, RVL Pharmaceuticals plc, and its subsidiaries other than the RVL Subsidiaries will promptly commence, and RVL Pharmaceuticals plc’s public equity is expected to be cancelled upon completion of its wind-down during 2024, resulting in no recovery to public shareholders.
Retrieved on:
Thursday, October 12, 2023
Bankruptcy,
Pharmacy,
Interest,
LLP,
RVL,
Ernst & Young,
Corporate action,
Growth,
United States bankruptcy court,
United States Bankruptcy Court for the Southern District of New York,
Ropes & Gray,
Blepharoplasty,
Patient,
Security (finance),
Financial services,
Athyrium BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals, Inc. and RVL Pharmacy, LLC (the “RVL Subsidiaries”), have reached an agreement with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”), and other key stakeholders, to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”). The Reorganization provides a structured pathway for the RVL Subsidiaries to significantly reduce their debt, while enabling them to streamline operations, maintain jobs and position themselves under new ownership. As a result of the Reorganization, RVL is expected to commence the wind-down of any remaining operations of the Company and its subsidiaries, other than the RVL Subsidiaries. RVL’s public equity is expected to be cancelled upon completion of its wind-down, anticipated to be during 2024, likely resulting in no recovery to public shareholders.
Key Points:
- The Reorganization provides a structured pathway for the RVL Subsidiaries to significantly reduce their debt, while enabling them to streamline operations, maintain jobs and position themselves under new ownership.
- As a result of the Reorganization, RVL is expected to commence the wind-down of any remaining operations of the Company and its subsidiaries, other than the RVL Subsidiaries.
- The Reorganization contemplates that all of RVL Subsidiaries’ vendors, suppliers, and customers will be unaffected by the Reorganization, and their employees will remain employed by these entities.
- The RVL Subsidiaries have filed a series of “First Day Motions” with the United States Bankruptcy Court for the District of Delaware.
Retrieved on:
Wednesday, October 4, 2023
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Wednesday, August 23, 2023
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows:
Key Points:
- BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows:
Retrieved on:
Wednesday, August 16, 2023
Exercise,
Blepharoplasty,
Telephone,
Act,
Park Avenue,
Peer-to-peer file sharing,
Regulation D,
The Act,
Sale,
3rd Floor,
Prospectus,
Form,
Security (finance) The closing of the offering is expected to occur on or about August 18, 2023, subject to the satisfaction of customary closing conditions.
Key Points:
- The closing of the offering is expected to occur on or about August 18, 2023, subject to the satisfaction of customary closing conditions.
- The gross proceeds to the Company from the registered direct offering are expected to be approximately $5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- The offering of the ordinary shares in the registered direct offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
- A final prospectus supplement and accompanying prospectus relating to the ordinary shares being offered in the registered direct offering will be filed with the SEC.
Insurance,
Blepharoplasty,
Marketing,
Tax,
GAAP,
Sale,
Medication,
Development,
Depreciation,
Growth,
TAM,
Research,
Adjustment,
Colin Markison,
RVL,
Bank,
Pharmaceutical industry,
Fine chemical,
Reinsurance,
Cryptocurrency,
Bookkeeping,
EBITDA,
Athyrium -- The Company streamlined operating expense in order to extend runway, optimize marketing mix, and support strategic business development --
Key Points:
- UPNEEQ net product sales were $8.3 million, a decrease of $0.1 million, or 2%, from the second quarter of 2022.
- 5,400 cumulative unique medical aesthetics practices had placed orders for UPNEEQ at quarter end, an increase of 13% from the end of the first quarter of 2023.
- Adjusted EBITDA1 loss was $(7.4) million, compared to an Adjusted EBITDA loss of $(11.8) million in the second quarter of 2022.
- Adjusted EBITDA loss is reconciled from net loss, the most comparable GAAP financial measure, in the attached table “RVL Pharmaceuticals plc - GAAP to Non-GAAP Reconciliations” at the end of this press release.
Retrieved on:
Wednesday, August 2, 2023
Blood pressure,
Glaucoma,
Blepharoplasty,
Ptosis,
Orthostatic hypotension,
Hypotension,
Conference call,
Focal neurologic signs,
Stroke,
Cardiovascular disease,
Eye,
Orbit,
Myasthenia gravis,
Beta blocker,
Hypertension,
Telecanthus,
Ophthalmoparesis,
Metabolism,
Patient,
Xanthine oxidase inhibitor,
Risk,
Eye injury,
Glycosidic bond,
System,
Aneurysm,
Headache,
Conference,
Horner's syndrome,
Phosphorus,
Pharmaceutical industry UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
Key Points:
- UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
- Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses.
- Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
- Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
These include discussions to acquire a specific potential counterparty in an all stock strategic transaction and discussions with potential financing sources regarding incremental funding for the combined company in the event such a transaction is consummated.
Key Points:
- These include discussions to acquire a specific potential counterparty in an all stock strategic transaction and discussions with potential financing sources regarding incremental funding for the combined company in the event such a transaction is consummated.
- This strategic transaction, if consummated, would result in a more diversified aesthetics company with meaningful revenue and synergies.
- In addition, the Company is in business development discussions with other parties to further enhance the business on a go-forward basis.
- There is no certainty that the Company will enter into a strategic transaction or that any financing will be consummated.
BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the “Rules”) at the Company’s Annual General Meeting held on June 15, 2023 (the “AGM”).
Key Points:
- BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the “Rules”) at the Company’s Annual General Meeting held on June 15, 2023 (the “AGM”).
- The result of the poll was 36,568,508 votes for; and 390,152 votes against.
- There were 2,245,474 abstentions or withheld votes.
- In such circumstances, the Affected Parties will not incur an obligation under Rule 9 of the Rules to make a general offer to the Company's other shareholders.
Insurance,
Telehealth,
Blepharoplasty,
Marketing,
Tax,
Optometry,
Prescription,
GAAP,
Research,
Absorption,
Pharmacy,
Sale,
Medication,
Depreciation,
Growth,
Adjustment,
Colin Markison,
RVL,
Pharmaceutical industry,
Video game,
Cryptocurrency,
Bank,
Bookkeeping,
EBITDA -- UPNEEQ Won “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants --
Key Points:
- In fact, monthly pharmacy prescriptions reached an all-time high during the first quarter of 2023, despite the absence of personal promotional support.
- Additionally, momentum in aesthetics continued, with growth in the percentage of reorders and in new account openings during the quarter.
- UPNEEQ net product sales were $8.8 million, an increase of $2.9 million, or 49%, over the first quarter of 2022.
- Adjusted EBITDA loss is reconciled from net loss, the most comparable GAAP financial measure, in the attached table “RVL Pharmaceuticals plc - GAAP to Non-GAAP Reconciliations” at the end of this press release.
